Clinical trials: LAM
HIV Infection
Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV
This study was designed to test the safety and effectiveness of EPZICOM(abacavir/lamivudine) and TRUVADA (emtricitabine/tenofovir) for the treatment of HIV infection when both are used in combination with KALETRA…
- Trial name
- HEAT (NCT00244712)
- Testing
- emtricitabine/tenofovir, abacavir/lamivudine
- Where
- 74 sites in United States, Puerto Rico
- Volunteers
- 688 people
- Sponsor
- GlaxoSmithKline
HIV Infections
AVX754 (a New Nucleoside Reverse Transcriptase Inhibitor [NRTI]) to Treat Drug-resistant HIV
The study will measure how safe and effective AVX754 (a new drug for the treatment of HIV) is in treating HIV-1 infected people who have failed treatment with lamivudine.
- Trial name
- NCT00126880
- Testing
- AVX754, 3TC
- Where
- Australia
- Volunteers
- 52 people
- Sponsor
- Avexa
Infection, Human Immunodeficiency Virus
Evaluation of the Bioequivalence of a Combined Formulated Tablet
Dolutegravir (DTG, GSK1349572) is a next-generation integrase inhibitor (INI) currently in phase 3 clinical trials for human immunodeficiency virus (HIV).
- Trial name
- NCT01622790
- Testing
- Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg, Dolutegravir 50 mg, abacavir 600 mg/lamivudine 300 mg
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections
Antiretroviral Treatment Simplification Study With Efavirenz + Abacavir + 3TC Once Daily
To evaluate the proportion of patients with virological failure after 48 weeks of treatment with the combination of efavirenz 600 mg + lamivudine (3TC) 300 mg + abacavir 600 mg once daily as an antiretroviral simplification…
- Trial name
- NCT00314626
- Testing
- efavirenz, Abacavir+lamivudine
- Where
- 16 sites in Spain
- Volunteers
- 99 people
- Sponsor
- Germans Trias i Pujol Hospital
HIV -1 Infection
Establishment of a Database of HIV Subjects Initiating or Simplifying Dual Therapy With Dolutegravir/Lamivudine
The introduction of combination antiretroviral therapy (cART) has completely revolutionized the management of HIV-positive patients, drastically reducing HIV-associated mortality and morbidity.
- Trial name
- NEW_ODOACRE (NCT06637813)
- Testing
- Blood sampling for evaluation of biomarkers
- Volunteers
- 1,220 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
HIV Infections
Safety and Effectiveness of Four Anti-HIV Drug Combinations in HIV-Infected Children and Teens
The purpose of this study is to see if it is safe and effective to give HIV-infected children and teens 1 of 4 anti-HIV drug combinations. Decreasing HIV levels in infected patients can slow down disease progression.
- Trial name
- NCT00001091
- Testing
- Ritonavir, Nelfinavir mesylate, Nevirapine
- Where
- 55 sites in United States, Puerto Rico
- Volunteers
- 200 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Comparing Continuing Tenofovir, Emtricitabine (or Lamivudine) Plus Lopinavir and Switching to Raltegravir Plus Darunavir
The main objective of this clinical trial in randomizing HIV infected patients under good HIV control with tenofovir (TDF), emtricitabine (or lamivudine) plus lopinavir/ritonavir (LPV/r) into switching the regimen to raltegravir…
- Trial name
- SPARE (NCT01294761)
- Testing
- Raltegravir, Darunavir/r
- Where
- Japan
- Volunteers
- 59 people
- Sponsor
- National Center for Global Health and Medicine, Japan
HIV Infections
ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Naïve HIV-Infected Subjects
To assess the safety, tolerability and antiviral activity of lopinavir/ritonavir when administered orally in antiretroviral-HIV-1 infected subjects.
- Trial name
- NCT00004578
- Testing
- Lopinavir/Ritonavir, Lamivudine, Stavudine
- Where
- 10 sites in United States
- Volunteers
- 100 people
- Sponsor
- Abbott
Infection, Human Immunodeficiency Virus I
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
The purpose of this trial is to assess the non-inferior antiviral activity of GSK1349572 50 mg plus Abacavir/Lamivudine once daily versus Efavirenz/Emtricitabine/Tenofovir disoproxil fumarate (ATRIPLA® a trade mark of…
- Trial name
- NCT01263015
- Testing
- Dolutegravir, Atripla, Abacavir/Lamivudine
- Where
- 145 sites in United States, Australia and 10 more
- Volunteers
- 844 people
- Sponsor
- ViiV Healthcare
HIV Infections, Acquired Immunodeficiency Syndrome
A Study to Evaluate the Safety and Efficacy of an Investigational Drug in HIV Infected Patients (0518-004)(COMPLETED)
This is a study that will investigate the safety and efficacy of an investigational drug in Human immunodeficiency virus (HIV) infected patients.
- Trial name
- NCT00100048
- Testing
- Comparator: MK0518 monotherapy, Comparator: MK0518 combination therapy, Comparator: efavirenz
- Volunteers
- 206 people
- Sponsor
- Merck Sharp & Dohme LLC
Liver Cirrhosis
Clinical Trial Multi-analyte Blood Test
This is a clinical trial designed to evaluate the performance of a multi-analyte blood test alone to ultrasound alone for the detection of HCC within a population that is at high risk for HCC due to liver cirrhosis.
- Trial name
- CLiMB (NCT03694600)
- Testing
- Multi-analyte blood Test
- Where
- 38 sites in United States
- Volunteers
- 1,900 people, healthy volunteers welcome
- Sponsor
- Helio Genomics
HIV Infections, AIDS
A Randomized Clinical Trial to Evaluate Solutions for the Management of Virologic Failure on TLD in Sub-Saharan Africa
The RESOLVE trial is an open, parallel arm, randomized clinical trial which aims to determine the optimal strategy for management of virologic failure on antiretroviral therapy (ART) with tenofovir, lamivudine, and dolutegravir…
- Conditions
- HIV Infections, AIDS, Virologic Failure
- Trial name
- RESOLVE (NCT05373758)
- Testing
- Standard of Care treatment strategy, Individualized Care treatment strategy, Immediate Switch
- Where
- 3 sites in South Africa, Uganda
- Volunteers
- 648 people
- Sponsor
- Massachusetts General Hospital
HIV Infection
A Prospective, Open-label Trial of Two ABC/3TC Based Regimens in Late Presenter naïve Patients (CD4 <200 Cells/µL)
1. PROTOCOL SUMMARY This is a prospective, randomized open-label, 2 arm, 3-phase trial to compare the 48-weeks virological response of two different regimens containing abacavir/lamivudine (abacavir/lamivudine…
- Trial name
- NCT01900106
- Testing
- abacavir/lamivudine + raltegravir, abacavir/lamivudine + darunavir/ritonavir
- Where
- Italy
- Volunteers
- 47 people
- Sponsor
- University of Modena and Reggio Emilia
HIV-1-infection
Early DOlutegravir/LAmivudine Switching After Virological Suppression (EDOLAS Study)
Phase III, randomized, open-label, multicentre, active-controlled, non-inferiority study evaluating the efficacy and safety of early switching to dolutegravir/lamivudine (DTG/3TC) in single-pill, in HIV-1 infected individuals…
- Trial name
- EDOLAS (NCT04979468)
- Testing
- DOVATO
- Where
- 25 sites in Italy
- Volunteers
- 440 people
- Sponsor
- Societa' Italiana Di Malattie Infettive E Tropicali
Hiv Infection With Antiretroviral Therapy Indication, CD4 Below 350/µL or Below 15%
Zidovudine / Lamivudine + Nevirapine Twice Daily, Versus Tenofovir + Lamivudine + Nevirapine Once Daily in ARV-Naive Patients
The study will compare the immuno-virological efficacy, and safety, of a once daily antiretroviral combination (tenofovir + lamivudine + nevirapine) versus a twice daily association (fixed dose combination of…
- Trial name
- NCT00199979
- Testing
- Nevirapine
- Where
- France
- Volunteers
- 250 people
- Sponsor
- MEDEX
Chronic Hepatitis B
Oxymatrine Plus Lamivudine Combination Therapy Versus Lamivudine Monotherapy for Chronic Hepatitis B Infected Subjects
The purpose of this study is to evaluate the efficacy of Oxymatrine plus Lamivudine Combination Therapy and whether it could lower the incidence of Lamivudine long-term resistance compared to Lamivudine Monotherapy.
- Trial name
- NCT02202473
- Testing
- Lamivudine, Lamivudine+Oxymatrine Capsules
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Southeast University, China
Hepatocellular Carcinoma
A Phase III Study in Post-operative HBV-related Hepatocellular Carcinoma
Research Objective and Study End Points To evaluate the anti-HBV as well as HCC recurrence reducing effects of standard (18 months) lamivudine treatment at time of HBV reactivation with hepatitis flare up (HBV DNA > 105 copies/mL…
- Trial name
- NCT00455091
- Testing
- Adefovir Dipivoxil and Lamivudine
- Where
- 8 sites in Taiwan
- Volunteers
- 117 people
- Sponsor
- National Health Research Institutes, Taiwan
HIV-1 Infection
Dolutegravir-Lamivudine as Dual Therapy in Naive HIV-Infected Patients: A Pilot Study
The purpose of this study is to evaluate the antiviral efficacy, safety and tolerability of dual therapy with 3TC and DTG as initial therapy among naïve HIV patients
- Trial name
- PADDLE (NCT02211482)
- Testing
- dolutegravir, lamivudine
- Where
- Argentina
- Volunteers
- 20 people
- Sponsor
- Fundación Huésped
HIV Infections
Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants
The First Long-Acting Injectable Regimen (FLAIR) study is being conducted to establish if human immunodeficiency virus type-1 (HIV-1) infected adult participants whose virus is virologically suppressed on an integrase inhibitor…
- Trial name
- NCT02938520
- Testing
- Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA)
- Where
- 108 sites in United States, Canada and 9 more
- Volunteers
- 631 people
- Sponsor
- ViiV Healthcare
HIV Infections
Tenofovir-lamivudine-dolutegravir Combination as Second-line ART: a Randomised Controlled Trial
The strategy to support virological suppression on second-line antiretroviral treatment (ART) includes the provision of ART that has a low pill burden, good tolerability, low toxicity, is easily monitored, has a high barrier to…
- Trial name
- ARTIST (NCT03991013)
- Testing
- Dolutegravir 50 mg
- Where
- South Africa
- Volunteers
- 192 people
- Sponsor
- University of Cape Town